Syndax Pharmaceuticals Inc — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-02-03

Reporting Person: Meyers Michael L. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-31	Common Stock	J	2665.00	$7.97	Acquired	13395.00	Direct
2021-01-31	Common Stock	J	1771.00	$12.00	Acquired	15166.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Stock Option (Right to Buy)	$21.36	A	80000.00	Acquired	2031-02-03	Common Stock (80000.00)	Direct

Footnotes

F1: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan.

F2: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan.

F3: 1/48th of the shares subject to the option shall vest monthly over a four-year period.